Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors

English version České info

Hepatitis C virus (HCV) naturally infects only humans and chimpanzees. The determinants responsible for this narrow species tropism are not well defined. Virus cell entry involves human scavenger receptor class B type I (SR-BI), CD81, claudin-1 and occludin. Among these, at least CD81 and occludin are utilized in a highly species-specific fashion, thus contributing to the narrow host range of HCV. We adapted HCV to mouse CD81 and identified three envelope glycoprotein mutations which together enhance infection of cells with mouse or other rodent receptors approximately 100-fold. These mutations enhanced interaction with human CD81 and increased exposure of the binding site for CD81 on the surface of virus particles. These changes were accompanied by augmented susceptibility of adapted HCV to neutralization by E2-specific antibodies indicative of major conformational changes of virus-resident E1/E2-complexes. Neutralization with CD81, SR-BI- and claudin-1-specific antibodies and knock down of occludin expression by siRNAs indicate that the adapted virus remains dependent on these host factors but apparently utilizes CD81, SR-BI and occludin with increased efficiency. Importantly, adapted E1/E2 complexes mediate HCV cell entry into mouse cells in the absence of human entry factors. These results further our knowledge of HCV receptor interactions and indicate that three glycoprotein mutations are sufficient to overcome the species-specific restriction of HCV cell entry into mouse cells. Moreover, these findings should contribute to the development of an immunocompetent small animal model fully permissive to HCV.

Vyšlo v časopise: Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors. PLoS Pathog 6(7): e32767. doi:10.1371/journal.ppat.1000978
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000978

Souhrn

Zdroje

1. LindenbachBD

ThielHJ

RiceCM

2007 Flaviviridae: The Viruses and Their Replication.

KnipeDM

HowleyPM

Fields Virology Philadelphia Lippincott Williams & Wilkins 1101 1152

2. SimmondsP

BukhJ

CombetC

DeleageG

EnomotoN

2005 Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42 962 973

3. GottweinJM

ScheelTK

JensenTB

LademannJB

PrentoeJC

2009 Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49 364 377

4. BrownRS

2005 Hepatitis C and liver transplantation. Nature 436 973 978

5. MannsMP

WedemeyerH

CornbergM

2006 Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 1350 1359

6. ZhuQ

GuoJT

SeegerC

2003 Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 77 9204 9210

7. UprichardSL

ChungJ

ChisariFV

WakitaT

2006 Replication of a hepatitis C virus replicon clone in mouse cells. Virol J 3 89

8. PlossA

EvansMJ

GaysinskayaVA

PanisM

YouH

2009 Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457 882 886

9. ThomssenR

BonkS

PropfeC

HeermannKH

KochelHG

1992 Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol Berl 181 293 300

10. AndreP

Komurian-PradelF

DeforgesS

PerretM

BerlandJL

2002 Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 76 6919 6928

11. NielsenSU

BassendineMF

BurtAD

MartinC

PumeechockchaiW

2006 Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 80 2418 2428

12. BarthH

SchaferC

AdahMI

ZhangF

LinhardtRJ

2003 Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278 41003 41012

13. AgnelloV

AbelG

ElfahalM

KnightGB

ZhangQX

1999 Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 96 12766 12771

14. OwenDM

HuangH

YeJ

GaleMJr

2009 Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 394 99 108

15. LozachPY

Lortat-JacobH

de LacroixdL

StaropoliI

FoungS

2003 DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 278 20358 20366

16. PohlmannS

ZhangJ

BaribaudF

ChenZ

LeslieGJ

2003 Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 77 4070 4080

17. CormierEG

DursoRJ

TsamisF

BoussemartL

ManixC

2004 L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A 101 14067 14072

18. ScarselliE

AnsuiniH

CerinoR

RoccaseccaRM

AcaliS

2002 The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21 5017 5025

19. PileriP

UematsuY

CampagnoliS

GalliG

FalugiF

1998 Binding of hepatitis C virus to CD81. Science 282 938 941

20. EvansMJ

von HahnT

TscherneDM

SyderAJ

PanisM

2007 Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446 801 805

21. LiuS

YangW

ShenL

TurnerJR

CoyneCB

2009 Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 83 2011 2014

22. DreuxM

DaoTV

FresquetJ

GuerinM

JuliaZ

2009 Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog 5 e1000310

23. BlanchardE

BelouzardS

GoueslainL

WakitaT

DubuissonJ

2006 Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80 6964 6972

24. TscherneDM

JonesCT

EvansMJ

LindenbachBD

McKeatingJA

2006 Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry. J Virol 80 1734 1741

25. FlintM

von HahnT

ZhangJ

FarquharM

JonesCT

2006 Diverse CD81 proteins support hepatitis C virus infection. J Virol 80 11331 11342

26. HaidS

WindischMP

BartenschlagerR

PietschmannT

2010 Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol 84 964 975

27. CataneseMT

AnsuiniH

GrazianiR

HubyT

MoreauM

2010 Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 84 34 43

28. DrummerHE

WilsonKA

PoumbouriosP

2002 Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J Virol 76 11143 11147

29. PetraccaR

FalugiF

GalliG

NoraisN

RosaD

2000 Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 74 4824 4830

30. FlintM

MaidensC

LoomisPL

ShottonC

DubuissonJ

1999 Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. Journal Of Virology 73 6235 6244

31. RoccaseccaR

AnsuiniH

VitelliA

MeolaA

ScarselliE

2003 Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 77 1856 1867

32. OwsiankaAM

TimmsJM

TarrAW

BrownRJ

HicklingTP

2006 Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80 8695 8704

33. DrummerHE

BooI

MaerzAL

PoumbouriosP

2006 A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol 80 7844 7853

34. RothwanglKB

ManicassamyB

UprichardSL

RongL

2008 Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Virol J 5 46

35. FriebeP

BoudetJ

SimorreJP

BartenschlagerR

2005 Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. J Virol 79 380 392

36. WitteveldtJ

EvansMJ

BitzegeioJ

KoutsoudakisG

OwsiankaAM

2009 CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 90 48 58

37. PietschmannT

KaulA

KoutsoudakisG

ShavinskayaA

KallisS

2006 Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103 7408 7413

38. BartoschB

VerneyG

DreuxM

DonotP

MoriceY

2005 An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79 8217 8229

39. ZhongJ

GastaminzaP

ChungJ

StamatakiZ

IsogawaM

2006 Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol 80 11082 11093

40. GroveJ

NielsenS

ZhongJ

BassendineMF

DrummerHE

2008 Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 82 12020 12029

41. KoutsoudakisG

HerrmannE

KallisS

BartenschlagerR

PietschmannT

2007 The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol 81 588 598

42. OwsiankaA

TarrAW

JuttlaVS

LavilletteD

BartoschB

2005 Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79 11095 11104

43. KeckZY

OpDB

HadlockKG

XiaJ

LiTK

2004 Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 78 9224 9232

44. KeckZY

LiTK

XiaJ

BartoschB

CossetFL

2005 Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol 79 13199 13208

45. KeckZY

XiaJ

CaiZ

LiTK

OwsiankaAM

2007 Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 81 1043 1047

46. KeckZY

LiTK

XiaJ

Gal-TanamyM

OlsonO

2008 Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 82 6061 6066

47. BartoschB

VitelliA

GranierC

GoujonC

DubuissonJ

2003 Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278 41624 41630

48. BankwitzD

SteinmannE

BitzegeioJ

CiesekS

FrieslandM

2010 Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site and Protects Conserved Neutralizing Epitopes. J Virol

49. GroveJ

HubyT

StamatakiZ

VanwolleghemT

MeulemanP

2007 Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol 81 3162 3169

50. YangW

QiuC

BiswasN

JinJ

WatkinsSC

2008 Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem 283 8643 8653

51. HarrisHJ

FarquharMJ

MeeCJ

DavisC

ReynoldsGM

2008 CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 82 5007 5020

52. PlossA

RiceCM

2009 Towards a small animal model for hepatitis C. EMBO Rep 10 1220 1227

53. NagaiT

IbataK

ParkES

KubotaM

MikoshibaK

2002 A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol 20 87 90

54. Berberich-SiebeltF

Klein-HesslingS

HeppingN

Santner-NananB

LindemannD

2000 C/EBPbeta enhances IL-4 but impairs IL-2 and IFN-gamma induction in T cells. Eur J Immunol 30 2576 2585

55. PhamHM

ArganarazER

GroschelB

TronoD

LamaJ

2004 Lentiviral vectors interfering with virus-induced CD4 down-modulation potently block human immunodeficiency virus type 1 replication in primary lymphocytes. J Virol 78 13072 13081

56. SteinmannE

BrohmC

KallisS

BartenschlagerR

PietschmannT

2008 Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J Virol 82 7034 7046

57. DullT

ZuffereyR

KellyM

MandelRJ

NguyenM

1998 A third-generation lentivirus vector with a conditional packaging system. J Virol 72 8463 8471

58. KalajzicI

StoverML

LiuP

KalajzicZ

RoweDW

2001 Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells. Virology 284 37 45

59. LindenbachBD

EvansMJ

SyderAJ

WolkB

TellinghuisenTL

2005 Complete replication of hepatitis C virus in cell culture. Science 309 623 626

60. SpearmanC

1908 The method of “right and wrong cases” (“constant stimuli”) without Gauss's formulae. British Journal of Psychology 2 227 242

61. KärberG

1931 Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv für experimentelle Pathologie und Pharmakologie 162 480 487

62. HadlockKG

LanfordRE

PerkinsS

RoweJ

YangQ

2000 Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74 10407 10416

63. OwsiankaA

ClaytonRF

Loomis-PriceLD

McKeatingJA

PatelAH

2001 Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82 1877 1883

64. KriegerSE

ZeiselMB

DavisC

ThumannC

HarrisHJ

2009 Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-Claudin-1 associations. Hepatology

65. KreyT

ThielHJ

RumenapfT

2005 Acid-resistant bovine pestivirus requires activation for pH-triggered fusion during entry. J Virol 79 4191 4200

66. SeglenPO

1979 Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J Toxicol Environ Health 5 551 560